Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials A. Passaro,F. De Marinis,H. Tu, K.K. Laktionov, J. Feng, A. Poltoratskiy, J. Zhao,E.-H. Tan,M. Gottfried,V. Lee,D. Kowalski,C.-T. Yang, B. Srinivasa, L. Clementi,W. Tang, D.C.-L. Huang, A. Cseh, K. Park, C. Zhou,Y.-L. WuANNALS OF ONCOLOGY（2019）引用 0|浏览101暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
